Skip to main content
Erschienen in: International Urogynecology Journal 5/2006

01.10.2006 | Original Article

Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin

verfasst von: Linda Cardozo, David Castro-Diaz, Marc Gittelman, Arwin Ridder, Moses Huang

Erschienen in: International Urogynecology Journal | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

The embarrassment and social stigma associated with urinary incontinence (UI) in overactive bladder syndrome (OAB) sufferers is a major reason for individuals to seek help for their condition. An analysis of 1,873 subjects with OAB with UI was conducted to assess the efficacy of solifenacin in reducing incontinence in a pooled population from four phase III clinical trials, stratified by severity of incontinence, urgency, and other key factors at baseline. Subjects were randomized to either 5 or 10 mg of solifenacin once daily or placebo for 12 weeks. More than 50% of the total population became continent at study end, with either dose of solifenacin (P<0.01 vs placebo). Significant reductions in incontinence episodes and higher rates of attainment of continence vs placebo were observed irrespective of age or severity of incontinence or urgency at baseline with solifenacin treatment. Treatment was well tolerated, with the majority of adverse events being mild in nature. Solifenacin is an effective antimuscarinic agent for the treatment of incontinence associated with OAB.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49PubMedCrossRef Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49PubMedCrossRef
2.
Zurück zum Zitat Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766PubMedCrossRef Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766PubMedCrossRef
3.
Zurück zum Zitat Milsom I, Stewart W, Thuroff J (2001) The prevalence of overactive bladder. Am J Manag Care 6(11):S565–S573 Milsom I, Stewart W, Thuroff J (2001) The prevalence of overactive bladder. Am J Manag Care 6(11):S565–S573
4.
Zurück zum Zitat Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3):461–465PubMedCrossRef Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3):461–465PubMedCrossRef
5.
Zurück zum Zitat Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW et al (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78(6):687–695PubMedCrossRef Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW et al (2003) Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78(6):687–695PubMedCrossRef
6.
Zurück zum Zitat Cardozo L (2004) Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924PubMedCrossRef Cardozo L (2004) Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924PubMedCrossRef
7.
Zurück zum Zitat Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93(3):303–310PubMedCrossRef Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93(3):303–310PubMedCrossRef
8.
Zurück zum Zitat Gittelman M (2003) The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study (abstract TP76). Int J Gynecol Obstet 83(Suppl 3):94 Gittelman M (2003) The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study (abstract TP76). Int J Gynecol Obstet 83(Suppl 3):94
9.
Zurück zum Zitat Gittelman M, Kaufman J (2003) Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. Presented at the 17th International Federation of Gynecology and Obstetrics World Congress, Santiago, Chile, 2–7 November 2003 Gittelman M, Kaufman J (2003) Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. Presented at the 17th International Federation of Gynecology and Obstetrics World Congress, Santiago, Chile, 2–7 November 2003
10.
Zurück zum Zitat Ouslander JG (2002) Geriatric considerations in the diagnosis and management of overactive bladder. Urology 60(5 Suppl 1):50–55PubMedCrossRef Ouslander JG (2002) Geriatric considerations in the diagnosis and management of overactive bladder. Urology 60(5 Suppl 1):50–55PubMedCrossRef
11.
Zurück zum Zitat Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336PubMed Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336PubMed
12.
Zurück zum Zitat Kobelt G (1997) Economic considerations and outcome measurement in urge incontinence. Urology 50(6A Suppl):100–107PubMedCrossRef Kobelt G (1997) Economic considerations and outcome measurement in urge incontinence. Urology 50(6A Suppl):100–107PubMedCrossRef
13.
Zurück zum Zitat Coyne KS, Zhou Z, Thompson C, Versi E (2003) The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 92(7):731–735PubMedCrossRef Coyne KS, Zhou Z, Thompson C, Versi E (2003) The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 92(7):731–735PubMedCrossRef
14.
Zurück zum Zitat Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R et al (2004) The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7(4):455–463PubMedCrossRef Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R et al (2004) The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 7(4):455–463PubMedCrossRef
Metadaten
Titel
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin
verfasst von
Linda Cardozo
David Castro-Diaz
Marc Gittelman
Arwin Ridder
Moses Huang
Publikationsdatum
01.10.2006
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 5/2006
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-005-0058-6

Weitere Artikel der Ausgabe 5/2006

International Urogynecology Journal 5/2006 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.